Article

VMA treatment approved

The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).

Related Videos
Related Content
A history of the femtosecond laser in the United States and Europe
October 25th 2024

A history of the femtosecond laser in the United States and Europe

Week in Review - October 5, 2024
October 13th 2024

Week in Review - October 5, 2024

Factors affecting ROP development in the 8 weeks following birth
October 24th 2024

Factors affecting ROP development in the 8 weeks following birth

EyePod: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD
October 11th 2024

Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD

First patient dosed in clinical trial to treat neuropathic corneal pain
October 23rd 2024

First patient dosed in clinical trial to treat neuropathic corneal pain

The top 10 takeaways from AAO 2024
October 23rd 2024

The top 10 takeaways from AAO 2024

© 2024 MJH Life Sciences

All rights reserved.